{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:46:30Z","timestamp":1788522390562,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Mega-project for Innovative Drugs","award":["2019ZX09721001"],"award-info":[{"award-number":["2019ZX09721001"]}]},{"DOI":"10.13039\/501100019018","name":"CAMS Initiative for Innovative Medicine","doi-asserted-by":"crossref","award":["2016-I2M-3-014"],"award-info":[{"award-number":["2016-I2M-3-014"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81273427"],"award-info":[{"award-number":["81273427"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803413"],"award-info":[{"award-number":["81803413"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Peking Union Medical College Youth Fund","award":["33320140177 & 3332016139"],"award-info":[{"award-number":["33320140177 & 3332016139"]}]},{"DOI":"10.13039\/100016692","name":"Key R&D Program of Ningxia","doi-asserted-by":"crossref","award":["2018BFG02004"],"award-info":[{"award-number":["2018BFG02004"]}],"id":[{"id":"10.13039\/100016692","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["2018PT31010 and 2019PT350004"],"award-info":[{"award-number":["2018PT31010 and 2019PT350004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Infections caused by drug-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      , especially vancomycin-intermediate\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (VISA), leave clinicians with limited therapeutic options for treatment. Persister cells is a leading cause of recalcitrant infection and antibiotic treatment failure, and there is no drug in clinical use that specifically targets persister cells currently. Here, we report a promising combination therapy of sodium new houttuyfonate (SNH) and berberine chloride (BBR) which is able to eradicate both growing and persistent drug-resistant\n                      <jats:italic>Staphylococcus aureus.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The susceptibility test showed SNH exhibited anti-MRSA activity with MIC\n                      <jats:sub>90<\/jats:sub>\n                      at 64\u2009\u03bcg\/mL, while BBR showed weak anti-MRSA activity with MIC\n                      <jats:sub>90<\/jats:sub>\n                      at 512\u2009\u03bcg\/mL. MICs of BBR in combination with 1\/2 MIC SNH decreased by 4 to 64 folds compared with MICs of BBR alone. The results of time-killing assays revealed that the combined use of sub-MIC SNH and BBR offered an in vitro synergistic action against growing MRSA (including pathogenic MRSA) and VISA strains. More importantly, the combination of SNH and BBR was able to eradicate VISA Mu50 and pathogenic MRSA persister cells. The synergistic effect is likely related to the interruption of the cell membrane caused by SNH, which is confirmed by scanning electron microscope and membrane potential and permeability analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our study provide a promising clinical curative strategy for combating drug-resistant\n                      <jats:italic>S. aureus<\/jats:italic>\n                      infections, especially for recalcitrant infections caused by persister cells.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12866-020-02003-2","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T10:03:12Z","timestamp":1603101792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The combined antibacterial effects of sodium new houttuyfonate and berberine chloride against growing and persistent methicillin-resistant and vancomycin-intermediate Staphylococcus aureus"],"prefix":"10.1186","volume":"20","author":[{"given":"Xue","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongying","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiukun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"issue":"8","key":"2003_CR1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM199808203390806","volume":"339","author":"FD Lowy","year":"1998","unstructured":"Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339(8):520\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"2003_CR2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1073\/pnas.0710217105","volume":"105","author":"AD Kennedy","year":"2008","unstructured":"Kennedy AD, et al. Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc Natl Acad Sci. 2008;105(4):1327\u201332.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"2003_CR3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CMR.00081-09","volume":"23","author":"MZ David","year":"2010","unstructured":"David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23(3):616\u201387.","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"2003_CR4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrmicro2200","volume":"7","author":"HF Chambers","year":"2009","unstructured":"Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629\u201341.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"2003_CR5","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/femsre\/fux007","volume":"41","author":"TJ Foster","year":"2017","unstructured":"Foster TJ. Antibiotic resistance in Staphylococcus aureus. Current status and future prospects. FEMS Microbiol Rev. 2017;41(3):430\u201349.","journal-title":"FEMS Microbiol Rev"},{"issue":"1","key":"2003_CR6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","volume":"23","author":"BP Howden","year":"2010","unstructured":"Howden BP, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23(1):99\u2013139.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"2003_CR7","first-page":"269","volume":"90","author":"WA McGuinness","year":"2017","unstructured":"McGuinness WA, Malachowa N, DeLeo FR. Focus: infectious diseases: vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017;90(2):269.","journal-title":"Yale J Biol Med"},{"issue":"5","key":"2003_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nmicrobiol.2016.51","volume":"1","author":"BP Conlon","year":"2016","unstructured":"Conlon BP, et al. Persister formation in Staphylococcus aureus is associated with ATP depletion. Nat Microbiol. 2016;1(5):1\u20137.","journal-title":"Nat Microbiol"},{"issue":"1","key":"2003_CR9","first-page":"1","volume":"8","author":"Y Wang","year":"2018","unstructured":"Wang Y, et al. Inactivation of TCA cycle enhances Staphylococcus aureus persister cell formation in stationary phase. Sci Rep. 2018;8(1):1\u201313.","journal-title":"Sci Rep"},{"issue":"6318","key":"2003_CR10","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf4268","volume":"354","author":"A Harms","year":"2016","unstructured":"Harms A, Maisonneuve E, Gerdes K. Mechanisms of bacterial persistence during stress and antibiotic exposure. Science. 2016;354(6318):aaf4268.","journal-title":"Science"},{"key":"2003_CR11","doi-asserted-by":"crossref","unstructured":"Fisher RA, Gollan B, Helaine S. Persistent bacterial infections and persister cells. Nat Rev Microbiol. 2017;15(8):453\u201364.","DOI":"10.1038\/nrmicro.2017.42"},{"key":"2003_CR12","doi-asserted-by":"crossref","unstructured":"Brauner A, et al. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol. 2016;14(5):320\u201330.","DOI":"10.1038\/nrmicro.2016.34"},{"issue":"5690","key":"2003_CR13","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1126\/science.1099390","volume":"305","author":"NQ Balaban","year":"2004","unstructured":"Balaban NQ, et al. Bacterial persistence as a phenotypic switch. Science. 2004;305(5690):1622\u20135.","journal-title":"Science"},{"issue":"9","key":"2003_CR14","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/np980044+","volume":"61","author":"K Iwasa","year":"1998","unstructured":"Iwasa K, et al. Antimicrobial activity of 8-alkyl-and 8-phenyl-substituted berberines and their 12-bromo derivatives. J Nat Prod. 1998;61(9):1150\u20133.","journal-title":"J Nat Prod"},{"key":"2003_CR15","doi-asserted-by":"crossref","first-page":"12155","DOI":"10.1038\/srep12155","volume":"5","author":"R Feng","year":"2015","unstructured":"Feng R, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015;5:12155.","journal-title":"Sci Rep"},{"issue":"11","key":"2003_CR16","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/ptr.5475","volume":"29","author":"C Chen","year":"2015","unstructured":"Chen C, et al. A randomized clinical trial of berberine hydrochloride in patients with diarrhea-predominant irritable bowel syndrome. Phytother Res. 2015;29(11):1822\u20137.","journal-title":"Phytother Res"},{"issue":"8","key":"2003_CR17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1099\/jmm.0.000106","volume":"64","author":"N Guo","year":"2015","unstructured":"Guo N, et al. The synergy of berberine chloride and totarol against Staphylococcus aureus grown in planktonic and biofilm cultures. J Med Microbiol. 2015;64(8):891\u2013900.","journal-title":"J Med Microbiol"},{"issue":"1","key":"2003_CR18","volume":"19","author":"J Tan","year":"2019","unstructured":"Tan J, et al. Antimicrobial characteristics of Berberine against prosthetic joint infection-related Staphylococcus aureus of different multi-locus sequence types. BMC Complement Altern Med. 2019;19(1):218.","journal-title":"BMC Complement Altern Med"},{"issue":"1","key":"2003_CR19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/molecules24010103","volume":"24","author":"H Cui","year":"2018","unstructured":"Cui H, et al. Preparation and evaluation of Antidiabetic agents of Berberine organic acid salts for enhancing the bioavailability. Molecules. 2018;24(1):103.","journal-title":"Molecules"},{"issue":"11","key":"2003_CR20","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1007\/s11274-014-1712-2","volume":"30","author":"R-m Liang","year":"2014","unstructured":"Liang R-m, et al. Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). World J Microbiol Biotechnol. 2014;30(11):2861\u20139.","journal-title":"World J Microbiol Biotechnol"},{"issue":"4","key":"2003_CR21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1089\/jmf.2005.8.454","volume":"8","author":"H-H Yu","year":"2005","unstructured":"Yu H-H, et al. Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. J Med Food. 2005;8(4):454\u201361.","journal-title":"J Med Food"},{"issue":"9","key":"2003_CR22","doi-asserted-by":"crossref","first-page":"10322","DOI":"10.3390\/molecules170910322","volume":"17","author":"G-Y Zuo","year":"2012","unstructured":"Zuo G-Y, et al. Antibacterial and synergy of berberines with antibacterial agents against clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA). Molecules. 2012;17(9):10322\u201330.","journal-title":"Molecules"},{"key":"2003_CR23","doi-asserted-by":"publisher","unstructured":"Lu X, et al. In vitro activity of sodium new houttuyfonate alone and in combination with oxacillin or netilmicin against methicillin-resistant Staphylococcus aureus. PLoS One. 2013;8(7):e68053. https:\/\/doi.org\/10.1371\/journal.pone.0068053.","DOI":"10.1371\/journal.pone.0068053"},{"key":"2003_CR24","volume-title":"ACS Chemistry for Life","author":"Sodium new houttuyfonate","year":"2016","unstructured":"Sodium new houttuyfonate. ACS Chemistry for Life. 2016; Available from: https:\/\/www.acs.org\/content\/acs\/en\/molecule-of-the-week\/archive\/s\/sodium-new-houttuyfonate.html."},{"issue":"7","key":"2003_CR25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1248\/cpb.54.936","volume":"54","author":"H Lu","year":"2006","unstructured":"Lu H, et al. Variation in chemical composition and antibacterial activities of essential oils from two species of Houttuynia T HUNB. Chem Pharm Bull. 2006;54(7):936\u201340.","journal-title":"Chem Pharm Bull"},{"issue":"1-2","key":"2003_CR26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jep.2005.09.012","volume":"104","author":"H Lu","year":"2006","unstructured":"Lu H, et al. Anti-inflammatory effect of Houttuynia cordata injection. J Ethnopharmacol. 2006;104(1-2):245\u20139.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"2003_CR27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jep.2008.03.018","volume":"118","author":"K-M Lau","year":"2008","unstructured":"Lau K-M, et al. Immunomodulatory and anti-SARS activities of Houttuynia cordata. J Ethnopharmacol. 2008;118(1):79\u201385.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"2003_CR28","first-page":"1005","volume":"1","author":"E Endo","year":"2015","unstructured":"Endo E, Dias Filho B. Antibacterial activity of berberine against methicillin-resistant Staphylococcus aureus planktonic and biofilm cells. Austin J Trop Med Hyg. 2015;1(1):1005.","journal-title":"Austin J Trop Med Hyg"},{"issue":"1","key":"2003_CR29","volume":"16","author":"J-J Guo","year":"2016","unstructured":"Guo J-J, et al. The anti-Staphylococcus aureus activity of the phenanthrene fraction from fibrous roots of Bletilla striata. BMC Complement Altern Med. 2016;16(1):491.","journal-title":"BMC Complement Altern Med"},{"issue":"1","key":"2003_CR30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0378-1097(03)00856-5","volume":"230","author":"I Keren","year":"2004","unstructured":"Keren I, et al. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett. 2004;230(1):13\u20138.","journal-title":"FEMS Microbiol Lett"},{"issue":"3","key":"2003_CR31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","volume":"17","author":"M Tyers","year":"2019","unstructured":"Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol. 2019;17(3):141\u201355.","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"2003_CR32","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/ptr.5693","volume":"30","author":"M Imenshahidi","year":"2016","unstructured":"Imenshahidi M, Hosseinzadeh H. Berberis vulgaris and berberine: an update review. Phytother Res. 2016;30(11):1745\u201364.","journal-title":"Phytother Res"},{"issue":"6","key":"2003_CR33","volume":"10","author":"W Kim","year":"2015","unstructured":"Kim W, et al. Identification of an antimicrobial agent effective against methicillin-resistant Staphylococcus aureus Persisters using a fluorescence-based screening strategy. PLoS One. 2015;10(6):e0127640.","journal-title":"PLoS One"},{"issue":"1","key":"2003_CR34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2474","volume":"9","author":"JG Hurdle","year":"2011","unstructured":"Hurdle JG, et al. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol. 2011;9(1):62\u201375.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"2003_CR35","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1073\/pnas.030540597","volume":"97","author":"FR Stermitz","year":"2000","unstructured":"Stermitz FR, et al. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5\u2032-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci. 2000;97(4):1433\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"2003_CR36","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1055\/s-2002-36347","volume":"68","author":"FR Stermitz","year":"2002","unstructured":"Stermitz FR, et al. Two flavonols from Artemisa annua which potentiate the activity of berberine and norfloxacin against a resistant strain of Staphylococcus aureus. Planta Med. 2002;68(12):1140\u20131.","journal-title":"Planta Med"},{"key":"2003_CR37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejmech.2017.01.012","volume":"127","author":"J Wang","year":"2017","unstructured":"Wang J, et al. The synthesis and antistaphylococcal activity of 9, 13-disubstituted berberine derivatives. Eur J Med Chem. 2017;127:424\u201333.","journal-title":"Eur J Med Chem"},{"key":"2003_CR38","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ejmech.2018.08.050","volume":"157","author":"TY Fan","year":"2018","unstructured":"Fan TY, et al. Synthesis and antibacterial evaluation of 13-substituted cycloberberine derivatives as a novel class of anti-MRSA agents. Eur J Med Chem. 2018;157:877\u201386.","journal-title":"Eur J Med Chem"},{"key":"2003_CR39","unstructured":"Patel NAPRP, Patel RKPNJ. The formulation and evaluation of topical berberine-hydrochloride products. Pharm Technol. 2010;34(1). https:\/\/www.pharmtech.com\/view\/formulation-and-evaluation-topical-berberine-hydrochloride-products."},{"key":"2003_CR40","doi-asserted-by":"publisher","unstructured":"Buchanan B, et al. Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine. PLoS One. 2018;13(3):e0194979. https:\/\/doi.org\/10.1371\/journal.pone.0194979.","DOI":"10.1371\/journal.pone.0194979"},{"issue":"6","key":"2003_CR41","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3923\/rjmp.2011.650.669","volume":"5","author":"S Kapoor","year":"2011","unstructured":"Kapoor S, Saraf S. Topical herbal therapies an alternative and complementary choice to combat acne. Res J Med Plant. 2011;5(6):650\u20139.","journal-title":"Res J Med Plant"},{"issue":"1","key":"2003_CR42","first-page":"7","volume":"4","author":"AM Taghavi","year":"2012","unstructured":"Taghavi AM, et al. Effect of Berberine gel on periodontal inflammation: clinical and histological. J Periodontol. 2012;4(1):7\u201311.","journal-title":"J Periodontol"},{"issue":"12","key":"2003_CR43","first-page":"3","volume":"3","author":"G-J See","year":"2001","unstructured":"See G-J, et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with conventional methods in the management of patients with second-degree burns. MedGenMed. 2001;3(12):3\u201318.","journal-title":"MedGenMed"},{"key":"2003_CR44","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Institute, C.a.L.S","year":"2018","unstructured":"Institute, C.a.L.S. Performance standards for antimicrobial susceptibility testing. 28th ed. CLSI supplement M100; 2018.","edition":"28"},{"issue":"7346","key":"2003_CR45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10069","volume":"473","author":"KR Allison","year":"2011","unstructured":"Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature. 2011;473(7346):216\u201320.","journal-title":"Nature"},{"key":"2003_CR46","doi-asserted-by":"publisher","unstructured":"Shapiro HM, Nebe-von-Caron G. Multiparameter flow cytometry of bacteria, Methods Mol Biol.\u00a02004;263:33-44. https:\/\/doi.org\/10.1385\/1-59259-773-4:033.","DOI":"10.1385\/1-59259-773-4:033"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-020-02003-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-020-02003-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-020-02003-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T20:14:22Z","timestamp":1634588062000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-020-02003-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2003"],"URL":"https:\/\/doi.org\/10.1186\/s12866-020-02003-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-26433\/v1","asserted-by":"object"}]},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}